Notably, PGC-1α is downregulated in the skeletal muscle of patients with T2D and DPPIVis, such as sitagliptin, stimulate the PGC-1α synthesis [136] with protective effects against insulin resistance, skeletal muscle hypotrophy, and impaired glucose and lipid metabolism [137]. The gene discussed is PPARGC1A; the disease is Insulin resistance.